Background: The purpose of this study was (i) to test the hypothesis that combining Ki67 with residual cancer burden (RCB) following neoadjuvant chemotherapy, as the residual proliferative cancer burden (RPCB), provides significantly more prognostic information than either alone; (ii) to determine whether also integrating information on ER and grade improves prognostic power.
introduction
Pathological complete response ( pCR) following neoadjuvant chemotherapy is established as an intermediate marker of longterm outcome and a primary end point of many neoadjuvant studies, with those achieving a pCR having an excellent longterm outcome [1, 2] . The Food and Drug Administration (FDA) has published draft guidance to approve pCR as an end point for accelerated drug approval, subject to subsequent demonstration of improvements in disease-free survival (DFS) or overall survival (OS) [3] . Accelerated approval for the use of pertuzumab in combination with trastuzumab and chemotherapy in the neoadjuvant setting for HER2 + breast cancer has been granted based on improvements in pCR rate with the combination [4] . However, although a good predictor, pCR is imperfect, with the predictive power of pCR reported to vary significantly according to breast cancer subtype and some categories of patients without pCR have also been shown to have good prognosis [5] [6] [7] . Furthermore, improvements in pCR rate in neoadjuvant studies have not always correlated with improvements in long-term outcome [8] .
Prior studies have attempted to determine prognosis in patients who have received neoadjuvant chemotherapy using pathological measures of disease burden and/or biological characteristics of the tumour. In a large retrospective cohort study by our group, a high post-treatment Ki67 value measured on the surgical excision specimen was independently associated with poorer disease free and OS compared with patients with a low post-treatment Ki67 value [9] . Post-treatment Ki67 was found to be more predictive of long-term outcome than either the pre-treatment value or the change from pre-to post-treatment. This observation is also supported by similar findings by other groups [10] [11] [12] .
Residual cancer burden (RCB) was developed using bi-dimensional measurements of the residual tumour bed, nodal disease burden and invasive tumour cellularity of the post-treatment pathological specimen [13] . This score is continuous but is generally used to classify patients with residual disease into three risk groups (RCB class), which predict for distant relapse-free survival following neoadjuvant chemotherapy [13] . Despite these scoring systems, a substantial proportion of patients are still ultimately classed as having an intermediate prognosis.
The primary aim of this study was to test the hypothesis that addition of post-treatment Ki67 to RCB would provide more prognostic information than either Ki67 or RCB alone following neoadjuvant chemotherapy for primary breast cancer. Secondary exploratory analyses examined the additional prognostic information provided by post-treatment ER status (+ versus −) and histological grade and compared prognostic information in ER+ and ER− disease.
patients and methods

patient cohort
A total of 220 patients treated with neoadjuvant chemotherapy for primary breast cancer at the Royal Marsden Hospital were included in the study. Patients were identified retrospectively from a prospectively maintained hospital research database. Patients with stage IV disease were excluded, as were those without appropriate consent, insufficient pathological material available for review, or where sentinel lymph node biopsy had been carried out before administration of neoadjuvant chemotherapy (see supplementary Figure S1 , available at Annals of Oncology online for further details).
pathological assessment of residual disease RCB was determined on review of the H&E slides as described by Symmans et al. [13] . RCB0/pCR was defined as the absence of invasive cancer in the breast and lymph nodes. Ten per cent of cases were reviewed by an independent pathologist (SEP), which confirmed that RCB assessment was highly reproducible between observers (Spearman's r = 0.96). Post-treatment Ki67 was determined on formalin-fixed paraffin-embedded tissue using the MIB-1 antibody as described previously [9] . Ki67 score was defined as the percentage of the total number of carcinoma cells with nuclear staining, determined by exact counting. At least 5 fields and at least 500 cells (where possible) were scored which were selected to represent any possible areas of heterogeneous staining present in the sample, as per published guidelines [14] . The loss of tumour cellularity is recognized as a response to neoadjuvant chemotherapy [15, 16] . Therefore, where 500 cells were not present in exceptionally hypo-cellular samples despite increasing fields, criteria were revised to accept scores from at least 200 cells.
statistical methods
To test the hypothesis that Ki67 would complement RCB, these variables were entered into a Cox proportional hazards model to calculate relative event rates. The residual proliferative cancer burden (RPCB) was therefore calculated as the sum across all parameters of the Cox coefficient for the particular parameter, multiplied by the patient's parameter value. . [13] This score was used to classify patients with residual disease into tertiles to illustrate its prognostic ability. Prognostic indices (PIs) were also derived including post-treatment ER and histological grade from the output of a Cox model as for the RPCB (see supplementary Table S1 , available at Annals of Oncology online). The primary end point was time to recurrence (TTR), defined as the interval from surgery to time of recurrence. Follow-up times were censored at last follow-up if no recurrence had occurred or if patients had died without recurrence. Leave-one-out cross-validation (LOOCV) was used to reduce bias that arises due to the assessment and derivation of PIs within the same cohort. This was not carried out on RCB, which was derived externally. The multivariable fractional polynomials suite of programmes in Stata was used to assess the adequacy of the fitted models; this technique seeks the best functional relationship for a parameter for prediction of outcome [17] . The overall change in χ 2 was used to compare prognostic information from the PIs. Exploratory analyses were also undertaken to compare the prognostic performance of the PIs in ER+ and ER− breast cancer. Due to the relatively low number of events, multivariable fractional polynomials were not used for this analysis and scores were fitted as linear models.
results
patient and treatment characteristics
Patient demographics are shown in Table 1 . The median followup was 61 months. There were 66 recurrences and 49 deaths. The median age was 50 years. Half of all cases had T2 tumours and were node-positive at initial presentation. The majority had grade 2 or 3 tumours. Sixty-one per cent of cases were ER+ and 24% were HER2+. The majority of HER2+ cases received trastuzumab (42/53) and two-thirds received this neoadjuvantly. Nearly, all patients received anthracycline chemotherapy (98%) and the majority (64%) also received neoadjuvant taxanes. According to local practice at the time, before the routine use of neoadjvant taxanes, a proportion of patients treated with neoadjuvant anthracyclines went on to receive adjuvant taxane chemotherapy following surgery (15%). Just over half of patients were treated with breast conserving surgery.
validation of RCB as a predictor of long-term outcome
In this independent series, RCB class was confirmed to be highly predictive of long-term outcome (see supplementary Figure S2 , available at Annals of Oncology online and supplementary Table S2 , available at Annals of Oncology online). Further analyses of RCB for those with residual disease are presented using the score as a continuous variable for the ease of comparison with the other PIs (see Figure 1A and B). RCB tertiles were associated with significantly different clinical outcomes ( p het < 10 −7 ) for TTR and for OS ( p het < 10
−5
). A higher RCB score was associated with a shorter TTR ( p trend < 10
) and reduced OS ( p trend < 10
−7
). Those with scores in tertile 1 had 72% and 90% recurrence-free and OS rates, respectively, compared with 92% for both rates for patients with a pCR. Those patients in the third tertile had the worst long-term prognosis with only a 41% and 51% recurrence-free and OS rate, respectively (see supplementary Table S3, available Ki67 as a predictor of long term TTR and OS for patients with residual disease according to residual Ki67 score is summarized in Figure 1C and D and supplementary Table S3 , available at Annals of Oncology online. The cut-point between tertile 1 and 2 was 4.3% and scores above 17% were in the highest tertile. Similar to the prior findings from our group [9] , the post-treatment Ki67 on residual carcinoma following neoadjuvant chemotherapy was significantly prognostic ( p het < 10
) for TTR and ( p het < 10 −5 for OS) with higher values associated with shorter TTR ( p trend < 10
) and OS ( p trend < 10
). The lowest tertile had a 5-year recurrencefree rate at 5 years of 76% and OS rate of 87%. For those with the highest post-treatment Ki67 values, the outcome was poor with just a 33% recurrence-free rate and a 51% OS rate at 5 years.
RPCB as a predictor of long-term outcome
The relationship between the integrated score of RCB and Ki67 (RPCB) and long-term outcome is show in Figure 1E and F. The cut-point between tertile 1 and 2 was 2.80 and scores above 3.72 were in the highest tertile. RPCB score is seen to distinguish TTR ( p het < 10
) and OS ( p het < 10
) with greater accuracy than either RCB ( p het < 10 −7 for TTR and p het < 10 −5 for OS) or Ki67 ( p het < 10 −8 for TTR and p het < 10 −5 for OS) alone. Higher RPCB scores were associated with reduced TTR ( p trend < 10 −11 ) and OS ( p trend < 10
−9
). Patients with RPCB scores in the 1st tertile had a prognosis similar to those who achieved a pCR, with an 83% recurrence-free survival rate at 5 years and a 93% OS rate. Tertile 3 was associated with just a 34% recurrence-free and 46% OS rate at 5 years (see supplementary Table S3 , available at Annals of Oncology online).
comparison of prognostic models
All scores provided significant prognostic information (Table 2) . In this series, post-treatment Ki67 (χ 2 = 53.8) provided more prognostic information than RCB (χ 2 = 38.1). However, the primary objective of this study was to test the hypothesis that the addition of Ki67 to RCB to create RPCB would provide more prognostic information than either alone. This was confirmed; RPCB (χ 2 = 61.4) provided more prognostic information than either RCB or Ki67 alone with a Δχ 2 of 23.3 for the addition of Ki67 to RCB, indicating highly significantly improved prognostic performance (P < 0.001). A PI including RCB, histological grade and ER (χ 2 = 65.8) provided similar prognostic information to the RPCB, while the most prognostic information was provided by a prognostic score including all variables (RCB, Ki67, grade and ER: χ 2 = 73.8).
performance of prognostic models in ER+ and ER− breast cancer
Exploratory analyses were undertaken to assess the performance of the PIs in ER+ and ER− disease separately. Overall, each of the PIs provided greater separation of outcomes in ER− than ER + disease (see supplementary Figure S3 , available at Annals of Oncology online). Table 2 summarizes a comparison of the prognostic performance of the PIs in ER+ and ER− disease. All PIs provided significant amounts of prognostic information, although PIs integrating Ki67, grade and ER did not perform significantly better than RCB alone in the separate ER+ and ER− subgroups; however, the numbers of events and the power to detect differences in these subgroups are substantially reduced. In a comparison of hazard ratios (HRs) for Ki67 after allowing for RCB score (see supplementary Figure S4 , available at Annals of Oncology online), there was no evidence to suggest that the additional prognostic information provided by Ki67 differed between ER+ and ER− disease. simple dichotomous classification of pCR and residual disease or yAJCC staging [13] . Our data provide independent validation of RCB as a robust predictor of long-term outcome following neoadjuvant chemotherapy. This study provides proof of principle that the integration of two established predictors of long-term outcome following neoadjuvant chemotherapy, i.e. post-treatment Ki67 with RCB as RPCB, provides more prognostic information than either RCB or Ki67 alone. Appropriate identification of patients at high risk of relapse following neoadjuvant chemotherapy could enable characterization of drivers of drug resistance [18] . Potential is also highlighted for the design of post-neoadjuvant adjuvant studies in these high-risk populations. The findings from this study are consistent with the observation that integration of information on tumour biology and disease extent has been shown to improve prediction of longterm outcome in the other settings. The addition of information on tumour staging in the clinical treatment score adds further prognostic information to both the IHC4 and molecular predictors in the adjuvant setting [19, 20] . Similarly, following neoadjuvant endocrine therapy, the addition of post-treatment Ki67 to staging information in the PEPI score improves prediction of long-term outcome [21] .
Exploratory analyses were conducted according to ER expression (+ versus −). The outcome for ER+ disease was better overall, although this may reflect the relatively short follow-up for the natural history of this disease. All PIs provided greater separation of outcome in ER− than ER+ disease; nonetheless, an ER+ population is identified who are at high risk of relapse despite adjuvant endocrine therapy.
Limitations of this study are that samples are drawn from a single institution and that patients received heterogeneous systemic treatment, although the large majority was treated with neoadjuvant anthracycline and taxane chemotherapy. As such, this cohort may be considered to be largely representative of a contemporary population. The pathological work up and reporting of residual disease was rigorous and allowed reconstruction of the residual tumour bed for assessment of RCB, which carried out similarly to the cohort it was developed on.
Further studies should assess the performance of RPCB by other groups and in other study populations. The performance of these indices to predict outcome in populations treated with different agents, including targeted therapies, should be investigated, as should the potential to predict differences in long-term outcome in neoadjuvant clinical trials. Ki67 is not currently routinely assessed in all laboratories. RCB and Ki67 assessment both require analyses beyond routine pathological work-up of residual disease. Furthermore, without standardization of validated methodologies, widespread clinical implementation of RPCB would be limited. However, in research studies, for the purposes of stratifying patients into post-neoadjuvant adjuvant studies, or identifying high-risk disease for molecular profiling, local assessment of Ki67 would not necessarily be required and could potentially be carried out in a central laboratory. International studies are also underway to create greater uniformity in Ki67 analysis [22] . The addition of ER and histological grade provided comparable prognostic information to the addition of Ki67 and a model including all variables provided the most prognostic information. In conclusion, the addition of Ki67 to RCB provided significantly more prognostic information that either Ki67 or RCB alone (Δχ 2 = 23.3). Exploratory analyses suggest that the incorporation of the ER and grade on the post-treatment excision specimen also improves prognostication and further investigation of these indices in predicting post neoadjuvant recurrence is warranted.
